More Diagnostics

Executive Summary

More Diagnostics is a privately held, US-based company that specializes in developing and manufacturing high-quality, liquid, human-based control materials for in vitro diagnostic (IVD) testing. Founded in 2019 and headquartered in San Diego, the company has established a niche in providing stable controls for immunosuppressant drug monitoring and cardiac markers, serving both clinical laboratories and IVD manufacturers. Operating as an OEM/contract manufacturer and supplier of proprietary controls, More Diagnostics emphasizes quality, regulatory compliance, and customized solutions. The company targets a critical segment of the diagnostics market: quality assurance tools that are essential for accurate and reliable test results, particularly in high-stakes areas like transplant patient management and cardiac care. With a focus on customer-specific formulations and robust stability, More Diagnostics aims to differentiate itself from larger competitors by offering tailored solutions and responsive service. The diagnostics quality controls market is growing steadily, driven by increasing regulatory scrutiny, demand for accuracy in personalized medicine, and the expansion of point-of-care testing. More Diagnostics is well-positioned to capture share through its specialized expertise and contract manufacturing capabilities. However, as a private company with no disclosed funding or valuation, growth may be constrained by limited capital. The company's success hinges on its ability to expand its product portfolio, secure regulatory approvals, and forge partnerships with IVD manufacturers. If it can leverage its technical strengths and navigate the competitive landscape, More Diagnostics could become a key player in the IVD quality controls space, though the path to significant scale remains uncertain.

Upcoming Catalysts (preview)

• Q4 2026Launch of new cardiac marker controls70% success
• Q2 2027FDA 510(k) clearance for expanded immunosuppressant control panel60% success
• Q1 2027Strategic OEM supply agreement with major IVD manufacturer50% success